Your questions answered
1. Why have the email addresses changed?
In February 2022, Viroclinics-DDL was acquired by Cerba Research. Consequently, from July 2023, our email addresses change to the new domain cerbaresearch.com. This change is part of our ongoing efforts to improve our communication infrastructure and streamline our operations under the name Cerba Research. As a result, we will no longer use our old email addresses.
2. Will my emails to viroclinics.com/ddl.nl be redirected to the receiver and for how long?
Yes, your emails will be automatically forwarded to the corresponding new email address for at least 3 months from the 1st of July 2023.
When sending an email to the ‘old’ account, you will receive an automatic reply, stating that your email will be forwarded. The message will also inform you about the new cerbaresearch.com email address of the person you have sent your email to. New email addresses are built as such: [email protected]
3. What do I have to do?
Once you have received the automatic reply, please save the new email address of your contact and use it as of now. In case you don’t know the new email address of your contact person or have passed the 3-months transition period, please get in touch with us via our website. Contact Us – Cerba Research
4. Will there be other changes?
Apart from the email address change, as of July 2023 we have also integrated the Viroclinics.com and ddl.nl website into the Cerba Research website. You will be able to find an overview of our advanced services on Cerbaresearch.com
There is no impact on current and future studies and projects. Our legal entity and bank account details will remain the same. The business and its operational activities will continue as usual, and you can remain assured of Viroclinics-DDL’s high quality services.
Reach out to our experts and see how we can help advance your clinical trialContact Us